CClinicalTrials.gg
CompletedNCT01837537Updated Jul 17, 2017Results posted

Respiration Rate V2.0 in a Hospital Setting

An observational study in Respiratory Rate, sponsored by Medtronic - MITG. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by Medtronic - MITG · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to meet the respiration rate accuracy specifications for the study pulse oximeter monitoring system (study device) in a hospitalized volunteer population when compared to established technologies for measuring parameters related to respiration, such as Capnograph Respiration Rate (RR)(CO2).

Read the detailed description

Volunteer subjects from a hospital setting (see specific inclusion/exclusion criteria) over the age of 18, male and female, who provide written informed consent prior to the procedure, and are without any contact skin allergies to adhesives found in standard pulse oximetry sensors. A cross section of demographics - cardiovascular, respiratory, and metabolic type cases should be considered for a broad distribution of medical and surgical patients.

The study consists of measuring parameters related to respiration in hospitalized volunteers by means of the Bedside Respiratory Patient Monitoring System with RR V2.0 (Nightingale). The production-equivalent Nightingale device and multiparameter reference devices will be attached to the subject via sensors, nasal cannulas and ECG leads and the information from all devices will be captured continuously for up to 40 minutes to allow for at least 30 minutes of artifact free data 30 minutes.

02

Conditions studied

  • Respiratory Rate
03

In context

Lead sponsor

Medtronic - MITG is the lead sponsor of 176 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Volunteer subjects from a hospital setting on the general care floor or general surgical care floor

Inclusion criteria

  • Male or female.
  • 18 years or older.
  • A patient at the study site on a General Care Floor or General Surgery Care Floor.
  • Subject is willing and able to provide written consent.

Exclusion criteria

Exclusion Criteria:

  • Subject is younger than 18.
  • Subject has severe contact allergies that may cause a reaction to standard adhesive materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors.
  • Subject has an abnormality that may prevent proper application of the device.
  • Subject is in atrial fibrillation.
  • Subject has a documented history of frequent premature ventricular contractions (PVCs), defined as greater than 3 in 30 seconds or greater than 6 in 60 seconds.
  • Subject has an implanted pacemaker.
  • Subject is unwilling or unable to sign informed consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (actual)
Patient registry
No

Groups and cohorts

  • no treatment

    no treatment, prospective observational

06

What researchers measure

Primary outcomes

  1. Mean Error (ME) +/- 1 Breath Per Minute, RR Sensor

    The software calculates respiration rate values via Adult Respiratory Sensor with a mean error of +/- 1 breath per minute relative to a capnography based reference. The Mean Error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the sensor and the Respiration Rate calculated from capnography).

    Time frame: up to 40 minutes of continuous monitoring

Secondary outcomes

  1. Mean Error (ME) +/- 1 Breath Per Minute, Max-N Sensor

    The software calculates respiration rate values via the Max-N Sensor with a mean error of +/- 1 breath per minute relative to a capnography based reference. The Mean Error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the sensor and the Respiration Rate calculated from capnography). The error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the Max-N sensor minus the Respiration Rate calculated from capnography.

    Time frame: up to 40 minutes of continuous monitoring

07

Results

Posted Feb 3, 2017

Participant flow

Participant flow — Overall Study
Milestoneno Treatment
Started90
Completed90
Not completed0

Outcome measures

PrimaryMean Error (ME) +/- 1 Breath Per Minute, RR Sensor

The software calculates respiration rate values via Adult Respiratory Sensor with a mean error of +/- 1 breath per minute relative to a capnography based reference. The Mean Error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the sensor and the Respiration Rate calculated from capnography).

Time frame:
up to 40 minutes of continuous monitoring
Reported as:
Mean · BrPM (breaths per minute)
Mean Error (ME) +/- 1 Breath Per Minute, RR Sensor
BrPM (breaths per minute)no Treatment
Mean Error (ME) +/- 1 Breath Per Minute, RR Sensor-0.82 ± 2.19
SecondaryMean Error (ME) +/- 1 Breath Per Minute, Max-N Sensor

The software calculates respiration rate values via the Max-N Sensor with a mean error of +/- 1 breath per minute relative to a capnography based reference. The Mean Error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the sensor and the Respiration Rate calculated from capnography). The error value estimates the mean difference in simultaneous estimates of respiration rate (the Respiration Rate calculated from the Max-N sensor minus the Respiration Rate calculated from capnography.

Time frame:
up to 40 minutes of continuous monitoring
Reported as:
Mean · BrPM
Mean Error (ME) +/- 1 Breath Per Minute, Max-N Sensor
BrPMno Treatment
Mean Error (ME) +/- 1 Breath Per Minute, Max-N Sensor-0.16 ± 2.85

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
no Treatment—0/90 (0%)0/90 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)no Treatment
Mean54.2 (18 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)no Treatment
Female40
Male50
Race (NIH/OMB)
Race (NIH/OMB)(Participants)no Treatment
American Indian or Alaska Native2
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American12
White76
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)no Treatment
United States90
08

Study locations

1 site
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01837537
Lead sponsor
Medtronic - MITG
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
Mar 2013
Primary completion
Aug 2013
Completion
Oct 2013
Results posted
Feb 3, 2017
Last update
Jul 17, 2017

Study contacts

Joshua Lumbley, MD
principal investigator · The Ohio State University Wexner Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion